• +1-646-491-9876
    • +91-20-67278686

    Search

    Burkholderia pseudomallei Infections (Melioidosis) Pipeline Review H1 2017

    Burkholderia pseudomallei Infections (Melioidosis) Pipeline Review H1 2017

    • Report Code ID: RW0001799277
    • Category Pharmaceuticals
    • No. of Pages 52
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H1 2017, provides an overview of the Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) pipeline landscape.

    Burkholderia pseudomallei are a gram negative, bipolar, aerobic, motile rod-shaped soil dwelling bacterium. The bacterium can infect both animals and humans through direct contact via inhalation, ingestion, or open wounds. Signs and symptoms include fever, cough, chest pain, headache and anorexia. Risk factors include liver disease, diabetes, and thalassemia.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Burkholderia pseudomallei Infections (Melioidosis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical stages are 8 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

    Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) .
    - The pipeline guide reviews pipeline therapeutics for Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Burkholderia pseudomallei Infections (Melioidosis) - Overview
    Burkholderia pseudomallei Infections (Melioidosis) - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Burkholderia pseudomallei Infections (Melioidosis) - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Burkholderia pseudomallei Infections (Melioidosis) - Companies Involved in Therapeutics Development
    Bavarian Nordic A/S
    Emergent BioSolutions Inc
    Grifols SA
    Soligenix Inc
    Syntiron LLC
    Burkholderia pseudomallei Infections (Melioidosis) - Drug Profiles
    ARD-3100 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ARD-3150 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Burkholderia pseudomallei vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Burkholderia vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    dusquetide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    EV-035 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GC-072 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    melioidosis vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SGX-943 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Infectious Diseases - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Burkholderia pseudomallei Infections (Melioidosis) - Dormant Projects
    Burkholderia pseudomallei Infections (Melioidosis) - Discontinued Products
    Burkholderia pseudomallei Infections (Melioidosis) - Product Development Milestones
    Featured News & Press Releases
    May 31, 2016: FDA Grants Soligenix "Fast Track" Designation for SGX943 for the Treatment of Melioidosis
    Feb 11, 2015: Preclinical Melioidosis Results Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC
    Aug 14, 2014: US DTRA to fund preclinical work on Evolva's antibiotic GC-072
    Feb 21, 2014: Bavarian Nordic's MVA-BN Vaccine Platform Selected By U.S. Department Of Defense For New Vaccine Development
    Feb 14, 2014: Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Burkholderia pseudomallei Infections (Melioidosis) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Bavarian Nordic A/S, H1 2017
    Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Emergent BioSolutions Inc, H1 2017
    Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Grifols SA, H1 2017
    Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Soligenix Inc, H1 2017
    Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Syntiron LLC, H1 2017
    Burkholderia pseudomallei Infections (Melioidosis) - Dormant Projects, H1 2017
    Burkholderia pseudomallei Infections (Melioidosis) - Discontinued Products, H1 2017

    List of Figures

    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Bavarian Nordic A/S
    Emergent BioSolutions Inc
    Grifols SA
    Soligenix Inc
    Syntiron LLC

    Request for Sample

    Report Url http://www.reportsweb.com//burkholderia-pseudomallei-infections-melioidosis-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//burkholderia-pseudomallei-infections-melioidosis-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//burkholderia-pseudomallei-infections-melioidosis-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments